NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

MEK抑制劑:現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析)

MEK Inhibitors Report - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024214
出版日期 內容資訊 英文 325 Pages
商品交期: 3-5個工作天內
價格
MEK抑制劑:現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV分析) MEK Inhibitors Report - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月09日內容資訊: 英文 325 Pages
簡介

本報告提供MEK抑制劑市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·適應症·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 MEK抑制劑療法的概要與流行病學研究

第4章 MEK抑制劑開發平台藥物推算核準時間軸

第5章 MEK抑制劑的市場規模的變化與預測(2020年∼2030年)

第6章 開發平台(管線)的洞察和基準預測

第7章 MEK抑制劑的交易趨勢

第8章 MEK抑制劑開發平台藥物的專利比較分析

第9章 風險調整淨現值(r-NPV分析)

第10章 競爭機會的評估

目錄
Product Code: GERPH1557

GervanoRA's pipeline analysis and opportunity assessment report "MEK Inhibitors - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed MEK Inhibitors pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in MEK Inhibitors drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the MEK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in MEK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the MEK Inhibitors historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current MEK Inhibitors Market (2020) and the Forecasted MEK Inhibitors Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of MEK Inhibitors Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the MEK Inhibitors Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of MEK Inhibitors Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MEK INHIBITORS THERAPIES OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: ESTIMATED APPROVAL TIMELINES OF MEK INHIBITORS PIPELINE DRUGS

CHAPTER 5: MEK INHIBITORS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 6: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 7: DEALS ACTIVITIES OF MEK INHIBITORS COMPETITIVE SPACE

CHAPTER 8: COMPARATIVE PATENT ANALYTICS OF MEK INHIBITORS PIPELINE DRUGS

CHAPTER 9: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 10: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE: LIST OF NEW ENTRANTS CONSIDERED FOR FORECASTING THE MEK INHIBITORS MARKET
  • TABLE: ESTIMATED R&D INVESTMENTS OF THE NEW ENTRANTS
  • TABLE: GLOBAL MEK INHIBITORS CURRENT GLOBAL MARKET (2020)
  • TABLE: MEK INHIBITORS GLOBAL MARKET FORECAST, 2021-2030
  • TABLE: COLLABORATION DEALS IN MEK INHIBITORS THERAPEUTIC AREA
  • TABLE: LICENSING DEALS IN MEK INHIBITORS THERAPEUTIC AREA
  • TABLE: FINANCING DEALS IN MEK INHIBITORS THERAPEUTIC AREA
  • TABLE: MERGER AND ACQUISITION DEALS IN MEK INHIBITORS THERAPEUTIC AREA
  • TABLE: MEK INHIBITORS PHASE III PIPELINE DRUGS
  • TABLE: MEK INHIBITORS PHASE II PIPELINE DRUGS
  • TABLE: MEK INHIBITORS PHASE I PIPELINE DRUGS
  • TABLE: PATENT ANALYSIS OF CLINICAL STAGE ASSETS ALONG WITH ANTICIPATED PATENT EXPIRY DATES
  • TABLE: PATENT ANALYSIS OF MEK INHIBITORS DRUGS CLINICAL STAGE ASSETS, REGIONAL COVERAGE
  • TABLE: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE: MEK INHIBITORS GLOBAL MARKET OPPORTUNITY, 2020
  • FIGURE: MEK INHIBITORS GLOBAL MARKET (2020-2030), SEGMENTED BY EXISTING AVAILABLE MARKET & NEW ENTRANTS MARKET
  • FIGURE: GLOBAL MEK INHIBITORS MARKET VALUES FROM 2020 TILL THE YEAR 2030, SEGMENTED BY REGION
  • FIGURE: PIPELINE SHARE OF MEK INHIBITORS BY HSD
  • FIGURE: PIPELINE ANALYTICS FOR MEK INHIBITORS BY STAGE OF DEVELOPMENT
  • FIGURE: PIPELINE ANALYTICS OF MEK INHIBITORS DRUGS BY GEOGRAPHY
  • FIGURE: PIPELINE ANALYTICS OF MEK INHIBITORS BY ROUTE OF ADMINISTRATION
  • FIGURE: PIPELINE ANALYTICS OF MEK INHIBITORS DRUGS BY MOLECULE TYPE VERSUS HSD
  • FIGURE: PIPELINE ANALYTICS OF MEK INHIBITORS DRUGS BY INDICATION TYPE
  • FIGURE: PIPELINE ANALYTICS OF MEK INHIBITORS DRUGS BY INDICATION TYPE VERSUS HSD
  • FIGURE: DEAL ANALYTICS BY DEAL TYPE
  • FIGURE: MEK INHIBITORS DRUG CANDIDATES AND THE PATENT EXPIRIES
  • FIGURE: ANALYTICS OF TOTAL COMPANIES BY HEADQUARTERS
  • FIGURE: ANALYTICS OF MEK INHIBITORS PIPELINE BY THE TYPE OF COMPANIES
  • FIGURE: MEK INHIBITORS PIPELINE ANALYTICS BY COMPANY TYPE VS OPPORTUNITY ASSESSMENTS